Hepion Pharmaceuticals, Inc. HEPA
We take great care to ensure that the data presented and summarized in this overview for Hepion Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in HEPA
Top Purchases
Top Sells
About HEPA
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Insider Transactions at HEPA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 27
2023
|
Peter Wijngaard Director |
BUY
Open market or private purchase
|
Direct |
2,500
+20.83%
|
$7,500
$3.05 P/Share
|
|
Nov 24
2023
|
Peter Wijngaard Director |
BUY
Open market or private purchase
|
Direct |
2,500
+26.31%
|
$7,500
$3.09 P/Share
|
|
Sep 19
2023
|
Peter Wijngaard Director |
BUY
Open market or private purchase
|
Direct |
1,000
+18.18%
|
$5,000
$5.64 P/Share
|
|
Sep 18
2023
|
Robert T Foster CEO and Director |
BUY
Open market or private purchase
|
Direct |
1,600
+3.07%
|
$8,000
$5.6 P/Share
|
|
Sep 15
2023
|
Peter Wijngaard Director |
BUY
Open market or private purchase
|
Direct |
2,000
+17.77%
|
$10,000
$5.55 P/Share
|
|
Sep 15
2023
|
Robert T Foster CEO and Director |
BUY
Open market or private purchase
|
Direct |
1,600
+3.17%
|
$8,000
$5.4 P/Share
|
|
Feb 18
2021
|
John T Cavan Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+40.32%
|
$20,000
$2.0 P/Share
|
|
Feb 18
2021
|
Robert T Foster CEO and Director |
BUY
Open market or private purchase
|
Direct |
20,000
+30.65%
|
$40,000
$2.0 P/Share
|
|
Feb 16
2021
|
Peter Wijngaard Director |
BUY
Open market or private purchase
|
Direct |
10,000
+25.0%
|
$20,000
$2.2 P/Share
|
|
Dec 18
2020
|
Peter Wijngaard Director |
BUY
Open market or private purchase
|
Direct |
20,000
+50.0%
|
$20,000
$1.91 P/Share
|
|
Dec 08
2020
|
Robert T Foster CEO and Director |
BUY
Open market or private purchase
|
Direct |
25,000
+49.74%
|
$25,000
$1.58 P/Share
|
|
Dec 02
2020
|
John P Brancaccio Chairman |
BUY
Open market or private purchase
|
Direct |
7,000
+49.97%
|
$7,000
$1.53 P/Share
|
|
Dec 01
2020
|
Gary S Jacob Director |
BUY
Open market or private purchase
|
Direct |
12,000
+49.88%
|
$12,000
$1.66 P/Share
|
|
Nov 25
2020
|
John T Cavan Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
4,500
+48.39%
|
$4,500
$1.62 P/Share
|